IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled… | ScholarDeck

Paper

IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies.

New research · Internal Medicine

Diabetes care · 1mo

Cohort studyDiabetes care· Jul 2026

IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies.

Cecilia Martinez Escobedo, Anna Birukov, Ralph Heijmans … Clemens Wittenbecher

Read paper

EndocrinologyCohort studyPrognosisQ1IF 15.8

Agalactosylated IgG N-glycans are associated with higher diabetic nephropathy risk.

IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies.

Cecilia Martinez Escobedo … Clemens Wittenbecher

Diabetes care · Jul 2026 · Q1 in Internal Medicine

Purpose

To examine whether IgG N-glycosylation patterns are prospectively associated with incident diabetic nephropathy and neuropathy.

Methods

We analyzed IgG N-glycosylation profiles in four cohorts: EPIC-Potsdam, DiaGene, GenoDiabMar, and Hoorn DCS.

n = 3,263 individuals

Results

more agalactosylated sugar chains on antibodies means higher kidney damage risk

HR 1.13 (95% CI 1.04 to 1.24)

CI excludes the null - significant

More results

Associations of IgG-GPs with incident neuropathy were rendered nonsignificant after multiple testing correction.

“

Conclusion

IgG N-glycosylation may reflect immune-related mechanisms relevant to diabetic nephropathy; but the evidence between IgG-GPs and diabetic neuropathy remains inconclusive.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

Cohort Study

13.5%

Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.

Review

“Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.”

Cohort Study

4.5 minutes

Each visual-field test averaged 4.5 minutes per eye.

Cohort Study

57%

eyes could see better after three ranibizumab injections

Case Report

siblings had PTEN mutation and intracranial hypertension

Cohort Study

13.16 mmHg

intraocular pressure was lower after hemodialysis

Cohort Study

HR=1.19

Every 1 mm wider portal vein was associated with a 19% higher rate of recurrent bleeding.

Cross-sectional

MYR 88,346.12

Average annual out-of-pocket expenditure for patients with cancer in Malaysia.